



U.S. CYCLIST RECEIVES TWO-YEAR SUSPENSION FOR r-EPO POSITIVE TEST

COLORADO SPRINGS, Colo. (April 13, 2005)

The United States Anti-Doping Agency (USADA) announced today the decision by an independent three-member arbitration panel from the Court of Arbitration for Sport (CAS), imposing a two-year suspension on Adam Bergman of Lino Lakes, Minn., an athlete in the sport of cycling, for a first-time doping violation. Bergman, 24, tested positive for the prohibited substance recombinant human Erythropoietin (r-EPO) during an out-of-competition test conducted by USADA on April 6, 2004, in advance of the 2004 Tour de Georgia.

As a synthetic hormone, r-EPO stimulates the body's production of red blood cells, thereby, increasing oxygen transport and aerobic power. r-EPO is prohibited under the USADA Protocol and the rules of the Union Cycliste International (UCI), the international federation for the sport of cycling, both of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency's (WADA) Prohibited List.

"The CAS Panel's decision affirms the efforts of the UCLA Laboratory and USADA to use advanced scientific methods to continue to narrow the gap between those who dope and those committed to upholding the rights of clean athletes to participate on a level playing field" said Terry Madden, USADA's chief executive officer.

Bergman received a two-year suspension to take effect on the day following the decision but will receive credit for the time he accepted and served a provisional suspension. Therefore, his suspension will end on July 22, 2006. Additionally, Bergman forfeits all competitive results and winnings since April 6, 2004, the date of the test, including his 11th place finish in the Tour de Georgia on April 25, 2004; his fifth place finish in the U.S. Cycling Federation Elite Men's National Time Trial Championship on June 17, 2004; and his second place finish at the 2004 Olympic Trials on June 19, 2004.

USA Cycling, the national governing body for the sport in the United States, will carry out the sanction.

USADA is responsible for managing the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement. USADA is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.

A copy of the CAS decision is available in the results management section of the official USADA Web site (<http://www.usantidoping.org>).

CONTACT:

Nirva Milord

Communications & Public Affairs Director

Phone: (719) 785-2009

E-mail: nmilord@usantidoping.org

United States Anti-Doping Agency
2550 Tenderfoot Hill St., Suite 200
Colorado Springs, CO 80906-7346
Phone: (719) 785-2000
Fax: (719) 785-2001
usada@usantidoping.org
<http://www.usantidoping.org>

Board of Directors

Ralph Hale, MD, Chair

Richard Cohen, MD, Vice Chair

Barry Axelrod, Treasurer

Kate Hendrickson Borg, Secretary

Evelyn Ashford

Lawrence Brown, MD, MPH

Jean Fourcroy, MD, PhD, MPH

Andrew Mecca, Dr. PH, MPH

Annette Salmeen, DPhil